Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Brian Meltzer
Date of Last Notice:	22nd December 2017

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	18th September 2020
No. of securities held prior to change	
Class	Unlisted Options
Number acquired	

	Shares	Options
Direct	-	1,250,000
Indirect	326,666	-
Total	**326,666**	**1,250,000**

	Shares	Options
Direct	-	7,000,000
Indirect	-	-
Total	-	**7,000,000**

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**-**</td><td>**-**</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3rd of September 2020.
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>8,250,000</td></tr><tr><td>**Indirect**</td><td>326,666</td><td>-</td></tr><tr><td>**Total**</td><td>**326,666**</td><td>**8,250,000**</td></tr></table>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr. David Sinclair
Date of Last Notice:	8th April 2019

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	18th September 2020
No. of securities held prior to change	
Class	Unlisted Options
Number acquired	

	Shares	Options
Direct	-	-
Indirect	-	-
Total	-	-

	Shares	Options
Direct	-	7,000,000
Indirect	-	-
Total	-	**7,000,000**

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**-**</td><td>**-**</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3rd of September 2020.
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>7,000,000</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**-**</td><td>**7,000,000**</td></tr></table>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Geoffrey Kempler
Date of Last Notice:	22nd December 2017

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity
Date of change	18th September 2020
No. of securities held prior to change	
Class	Unlisted Options
Number acquired	

No. of securities held prior to change

	Shares	Options
Direct	30,000	5,000,000
Indirect	17,981,000	-
Total	**18,011,000**	**5,000,000**

Number acquired

	Shares	Options
Direct	-	14,000,000
Indirect	-	-
Total	**-**	**14,000,000**

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>-</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3rd of September 2020.
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>30,000</td><td>19,000,000</td></tr><tr><td>**Indirect**</td><td>17,981,000</td><td>-</td></tr><tr><td>**Total**</td><td>**18,011,000**</td><td>**19,000,000**</td></tr></table>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Lawrence Gozlan
Date of Last Notice:	22nd December 2017

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	18th September 2020
No. of securities held prior to change	
Class	Unlisted Options
Number acquired	

	Shares	Options
Direct	-	1,250,000
Indirect	-	-
Total	**-**	**1,250,000**

	Shares	Options
Direct	-	7,000,000
Indirect	-	-
Total	-	**7,000,000**

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>-</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3rd of September 2020.
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>8,250,000</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>-</td><td>**8,250,000**</td></tr></table>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Peter Marks
Date of Last Notice:	22nd December 2017

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	18th September 2020
No. of securities held prior to change	
Class	Unlisted Options
Number acquired	

	Shares	Options
Direct	-	1,250,000
Indirect	43,111	-
Total	**43,111**	**1,250,000**

	Shares	Options
Direct	-	7,000,000
Indirect	-	-
Total	-	**7,000,000**

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**-**</td><td>**-**</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3rd of September 2020.
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>8,250,000</td></tr><tr><td>**Indirect**</td><td>43,111</td><td>-</td></tr><tr><td>**Total**</td><td>**43,111**</td><td>**8,250,000**</td></tr></table>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Alterity Therapeutics Limited (ASX:ATH)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Tristan Edwards
Date of Last Notice:	8th April 2019

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	18th September 2020
No. of securities held prior to change	
Class	Unlisted Options
Number acquired	

	Shares	Options
Direct	-	-
Indirect	-	-
Total	-	-

	Shares	Options
Direct	-	7,000,000
Indirect	-	-
Total	-	**7,000,000**

+ See chapter 19 for defined terms.

Number disposed	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>-</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**-**</td><td>**-**</td></tr></table>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the Notice of General Meeting of the Company approved on the 3rd of September 2020.
No. of securities held after change	<table><tr><th></th><th>Shares</th><th>Options</th></tr><tr><td>**Direct**</td><td>-</td><td>7,000,000</td></tr><tr><td>**Indirect**</td><td>-</td><td>-</td></tr><tr><td>**Total**</td><td>**-**</td><td>**7,000,000**</td></tr></table>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of incentive options under ESOP

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A